PPT Sues Biden Administration Over Menthol Cigarette Ban

Regulations by 2FIRSTS.ai
Apr.19.2024
PPT Sues Biden Administration Over Menthol Cigarette Ban
Public Trust Protection Organization (PPT) sues Biden administration over menthol cigarette ban, alleging violation of FOIA regulations.

According to a report by Fox News on April 17, the American watchdog group "Public Trust Protection Organization" (PPT) has filed a lawsuit against the Biden administration over the ban on menthol cigarettes.

 

The organization has filed a federal lawsuit against the Department of Health and Human Services (HHS), alleging violations of the Freedom of Information Act (FOIA). Last year, the organization submitted four FOIA requests to the department and its subsidiary agency, the Food and Drug Administration (FDA), regarding the ban on menthol cigarettes, but received no response to those requests.

 

The organization's chairman, Michael Chamberlain, was formerly a communications official at the Department of Education during the Trump administration. He stated in a press release:

 

The Biden administration and the FDA may have thought that they would be seen as conquering heroes when they announced the ban on menthol cigarettes. However, they quickly discovered that politics seemed much more complicated than that. This regulation is highly controversial, and it is important for the American public to understand the factors driving government action. Mr. Biden claims to be leading the most transparent government in history, but these agencies are not providing records. This seems to suggest that they do not want the public to know certain things.

 

According to the PowerPoint presentation, in the more than 90 days since the four requests were made, HHS has not provided any response. Therefore, the organization believes that HHS has not fulfilled its legal obligation to provide the required records for Freedom of Information Act requests.

 

Currently, the PPT has sought judicial review.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11
Belgium seizes 140,019 disposable vapes since the start of 2025 after sales ban took effect
Belgium seizes 140,019 disposable vapes since the start of 2025 after sales ban took effect
Belgium’s Federal Public Health Service said it has seized 140,019 disposable vapes since the start of 2025. The crackdown follows a ban on the sale of disposable e-cigarettes that came into force on January 1.
Dec.31 by 2FIRSTS.ai
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
As next-generation nicotine products become economically central rather than marginal, traditional volume-based metrics are increasingly unable to explain consumption, risk, and value. Units designed for a cigarette-based economy struggle to describe systems defined by delivery speed, pharmacokinetics, and adaptive user behavior. Drawing on financial reporting, regulation, and nicotine science, a fundamental question: can the future of nicotine still be measured using the tools of its past?
Feb.09 by Alan Zhao | 2Firsts Perspectives
EVO NXT 2026 Offers Unique Insights Into A Dynamic Industry
EVO NXT 2026 Offers Unique Insights Into A Dynamic Industry
Feb.09
China’s Nov. Vape Exports to U.S. Hold at $549 Million, Sustaining High After October’s $591 Million Peak
China’s Nov. Vape Exports to U.S. Hold at $549 Million, Sustaining High After October’s $591 Million Peak
China’s Nov. vape exports to the U.S. held at $549 million, following October’s $591 million record. 2025 YTD exports reached $3.72 billion, officially eclipsing 2024’s full-year total. This $1.14 billion 60-day surge signals a critical inventory overhang, heightening financial and regulatory risks for manufacturers.
Dec.22